ASIA Pharmaceutical Industries will continue to provide the Syrian National Market with essential medications in order to improve the health of the Syrian community.

ASIA is committed to making continuous improvements in its existing medications and its manufacturing plant, in order to defend its position as the premier company within the Syrian Pharmaceutical Industry.

ASIA will continue to seek new markets, with the world within its sight. And with the aim of entering the Western European Medical Market, ASIA is implementing the European Union’s GMP (EU-GMP) in its Manufacturing Plant.

Because of its eminent status within the Syrian Pharmaceutical Industry, ASIA Pharmaceutical Industries believes that it has the obligation to maintain high research standards within the Academic Society in general, and the Medical Society in particular

Realizing that diabetes is such a prevalent disease in Syria, and in our continued efforts to establish a healthy community, we plan on opening a Research and Development Centre for Diabetes in cooperation with the Syrian Diabetes Society